Skip to main content
SpringerLink
Log in

A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

The aim of this study is to investigate if serum asymmetric dimethylarginine (ADMA) levels can predict restenosis and major adverse cardiac events (MACE) in patients who undergo percutaneous coronary interventions. The most important cause of restenosis following percutaneous coronary intervention is neointimal hyperplasia. Nitric oxide (NO) prevents the neointimal hyperplasia growing. Asymmetric dimethylarginine is a competitive inhibitor of NO synthesis. The effect of ADMA on the restenosis has not yet been investigated. A total of 105 (80 male and 25 female) patients were included in our study. All patients underwent elective percutaneous transluminal coronary angioplasty (PTCA) with bare metal stent implantation or direct stenting for one coronary artery between September 2004 and January 2006. All patients were clinically followed for a period of 6 months, and a control angiography was performed at the end of this period. The probrain natriuretic peptide (pro-BNP), high-sensitivity Creactive protein (hs-CRP), and ADMA levels of the patients were evaluated before the procedure and 6 months afterwards. Biochemical parameters and angiographic features were evaluated in order to determine if they could predict the development of restenosis and MACE by using univariate and multivariate Cox regression analysis. The 65 (61.9%) patients (50 males and 15 females) who had not developed restenosis were designated as Group 1. The 27 (25.7%) patients (21 males and 6 females) who had developed restenosis were designated as Group 2. In terms of predicting the development of restenosis, the presence of diabetes mellitus (hazard ratio [HR]: 2.78; confidence interval [CI]: 1.25–6.20; P = 0.01), type of lesion (HR: 1.89; CI: 1.01–3.55; P = 0.04), form of procedure (HR: 0.30; CI: 0.11–0.81; P = 0.01), and ADMA (HR: 4.08; CI: 1.73–9.62; P = 0.001) were found to be significant in univariate Cox regression analysis. In contrast, only the levels of ADMA were found to be a significant predictor of restenosis in the multivariate Cox regression analysis (HR: 3.02; CI: 1.16–7.84; P = 0.02). The restenosis prediction of ADMA levels continued after excluding the patients with diabetes mellitus in the univariate and multivariate Cox regression analysis (HR: 5.23; CI: 1.99–13.76; P = 0.001 and HR: 5.61; CI: 1.79–17.62; P = 0.003, respectively). Regarding the development of cardiac events, hs-CRP (HR: 1.03; CI: 1.00–1.06; P = 0.01) and ADMA (HR: 17.1; CI: 3.06–95.8; P = 0.001) were found to be significantly correlated with adverse cardiac events in univariate Cox regression analysis, whereas only ADMA levels were significant in the multivariate Cox regression analysis (HR: 2.83; CI: 1.27–6.31; P = 0.01). The levels of ADMA obtained before the procedure predict the development of restenosis and MACE in patients who underwent elective PTCA and bare metal stent procedures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96:60–682.

    Article  PubMed  Google Scholar 

  2. Garg UC, Hassid A (1989) Nitric oxide-generating vasodilators and 8-bromo cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774–1777

    Article  CAS  PubMed  Google Scholar 

  3. Mooradian DL, Hutsell TC, Keefer LK (1995) Nitric oxide (NO) donor molecules: effect of NO release rates on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol 25: 674–678

    Article  CAS  PubMed  Google Scholar 

  4. Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP (1997). Nitric oxide regulates monocyte chemotactic protein-1. Circulation 96: 934–940

    CAS  PubMed  Google Scholar 

  5. Tran CT, Leiper JM, Vallance P (2003) The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4:33–40

    Article  CAS  PubMed  Google Scholar 

  6. Azuma H, Sato J, Hamasaki H, Sugimoto A, Isotani E, Obayashi S (1995) Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of L-arginine in regenerated endothelial cells. Br J Pharmacol 115:1001–1004

    CAS  PubMed  Google Scholar 

  7. Loscalzo J, Welch G (1995): Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38:87–104

    Article  CAS  PubMed  Google Scholar 

  8. Böger RH, Bode-Böger SM, Mügge A, Kienke S, Brandes R, Dwenger A, Frölich JC (1995). Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117:273–284

    Article  PubMed  Google Scholar 

  9. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S (1993) Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 334:170–174

    Article  CAS  PubMed  Google Scholar 

  10. Marks DS, Vita JA, Folts JD, Keaney JF Jr, Welch GN, Loscalzo J (1995) Inhibition of neointimal proliferation in rabbits following vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 96:2630–2638

    Article  CAS  PubMed  Google Scholar 

  11. Garg UC. Hassid A (1989) Nitric oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774–1777

    Article  CAS  PubMed  Google Scholar 

  12. Rainer H. Böger (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59:824–833

    Article  PubMed  CAS  Google Scholar 

  13. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R (2001) Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 358:2113–2117

    Article  CAS  PubMed  Google Scholar 

  14. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127–2128

    Article  CAS  PubMed  Google Scholar 

  15. Janero DR, Ewing JF (2000) Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential. Free Radic Biol Med 29:1199–1221

    Article  CAS  PubMed  Google Scholar 

  16. Lu TM, Ding YA, Charng MJ, Lin SJ (2003) Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 26:458–464

    Article  PubMed  Google Scholar 

  17. Wykretowicz A, Metzler L, Milewska A, Balinski M, Rutkowska A, Adamska K, Krauze T, Guzik P, Dziarmaga M, Wysocki H (2008) Noninvasively assessed pulsatility of ascending aortic pressure waveform is associated with the presence of coronary artery narrowing. Heart Vessels 23:16–19

    Article  PubMed  Google Scholar 

  18. Lenzen H, Tsikas D, Böger RH (2006) Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study. Eur J Clin Pharmacol 62:45–49

    Article  CAS  Google Scholar 

  19. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease. Circ Res 97:e53–e59

    Article  CAS  PubMed  Google Scholar 

  20. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, März W (2007) Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health Study) Clin Chem 53:273–283

    Article  CAS  PubMed  Google Scholar 

  21. Bae SW, Stühlinger MC, Yoo HS, Yu KH, Park HK, Choi BY, Lee YS, Pachinger O, Choi YH, Lee SH, Park JE (2005) Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 95:729–733

    Article  CAS  PubMed  Google Scholar 

  22. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC (2003) Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24:1912–1919

    Article  CAS  PubMed  Google Scholar 

  23. Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH, Kähler J (2005) Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 26:1846–1851

    Article  CAS  PubMed  Google Scholar 

  24. Fujita M, Nanto S, Oohara T, Morozumi T, Watanabe T, Nishio M, Awata M, Higo S, Oonishi T, Nagata S, Node K, Hori M, Kitakaze M (2002) Asymmetrical dimethyl arginine (ADMA) is a novel marker of coronary stent restenosis. Jpn Circ Soc Circ J 66suppl 1:41

    Google Scholar 

  25. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, Ueta Y, Nakashima Y, Yanagihara N (2004) Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthasedeficient mice. Arterioscler Thromb Vasc Biol 24:1682–1688

    Article  CAS  PubMed  Google Scholar 

  26. Tanaka M, Sydow K, Gunawan F, Jacobi J, Tsao PS, Robbins RC, Cooke JP (2005) dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 112:1549–1556

    Article  CAS  PubMed  Google Scholar 

  27. Bogle RG, MacAllister RJ, Whitley GSJ, Vallance P (1995) Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases. Am J Physiol 269: C750–C756

    CAS  PubMed  Google Scholar 

  28. Vallance P, Leiper J (2004) Cardiovascular biology of the asymmetric dimethylarginine: Dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24:1023–1030

    Article  CAS  PubMed  Google Scholar 

  29. Wojciak-Stothard B, Torondel B, Tsang LY, Fleming I, Fisslthaler B, Leiper JM, Vallance P. (2007) The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci 120: 929–942

    Article  CAS  PubMed  Google Scholar 

  30. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420–1426

    Article  PubMed  Google Scholar 

  31. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP (2002) Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106:987–992

    Article  CAS  PubMed  Google Scholar 

  32. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, Reaven GM, Tsao PS (2002) Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 51:843–846

    Article  CAS  PubMed  Google Scholar 

  33. Nash DT (2002) Insulin resistance, ADMA levels, and cardiovascular disease. JAMA 287:1451–1452

    Article  PubMed  Google Scholar 

  34. Geng DF, Jin DM, Wu W, Wang Z, Wang JF (2008) Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials. Atherosclerosis 202:521–528

    Article  PubMed  CAS  Google Scholar 

  35. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, DeVoe MC, Fakiolas CN, Pissimissis EG, Olympios CD, Foussas SG; Global Evaluation of New Events and Restenosis After Stent Implantation Study Group (2002) The impact of plasma levels of C-reactive protein, lipoprotein (a), and homocysteine on the long-term prognosis after successful coronary stenting. J Am Coll Cardiol 40:1375–1382

    Article  CAS  PubMed  Google Scholar 

  36. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A (1999) Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34:1512–1521

    Article  CAS  PubMed  Google Scholar 

  37. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schächinger V, Zeiher AM (2001) Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37:839–846

    Article  CAS  PubMed  Google Scholar 

  38. Hong YJ, Jeong MH, Lim SY, Lee SR, Kim KH, Sohn IS, Park HW, Kim JH, Kim W, Ahn Y, Cho JG, Park JC, Kang JC (2005) Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. Circ J 69:1477–1483

    Article  CAS  PubMed  Google Scholar 

  39. Lasave LI, Abizaid AA, Paiva e Maia J, de Ribamar Costa J Jr, Feres F, Mattos LA, Abizaid AS, Siqueira DA, Tanajura LF, Staico R, Beraldo de Andrade P, Braga SN, Sousa AG, Sousa JE (2007) Relationship between plasma C-reactive protein level and neointimal hyperplasia volume in patients with zotarolimus-eluting stents. Volumetric analysis by three-dimensional intracoronary ultrasound. Rev Esp Cardiol 60:923–931

    Article  PubMed  Google Scholar 

  40. Ozer N, Tangurek B, Firat F, Ozer S, Tartan Z, Ozturk R, Ozay B, Ciloglu F, Yilmaz H, Cam N (2008) Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Heart Vessels 23:75–82

    Article  PubMed  Google Scholar 

  41. Zairis MN, Ambrose JA, Manousakis SJ, Stefanidis AS, Papadaki OA, Bilianou HI, DeVoe MC, Fakiolas CN, Pissimissis EG, Olympios CD, Foussas SG (2002) The impact of plasma levels of c-reactive protein, lipoprotein (a) and homocysteine on the longterm prognosis after successful coronary stenting. J Am Coll Cardiol 40:1375–1382

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Bursa Postgraduate Hospital, 16330, Bursa, Turkey

    Hasan Ari, Selma Ari, Ercan Erdoğan, Vedat Koca & Tahsin Bozat

  2. Department of Cardiac Surgery, Bursa Postgraduate Hospital, Bursa, Turkey

    Osman Tiryakioğlu

  3. Department of Biochemistry, Bursa Şevket Yılmaz Hospital, Bursa, Turkey

    Yasemin Üstündağ

  4. Department of Biochemistry, Bursa Postgraduate Hospital, Bursa, Turkey

    Kağan Huysal

Authors
  1. Hasan Ari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Selma Ari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ercan Erdoğan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Osman Tiryakioğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasemin Üstündağ
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kağan Huysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vedat Koca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tahsin Bozat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hasan Ari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ari, H., Ari, S., Erdoğan, E. et al. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine. Heart Vessels 25, 19–26 (2010). https://doi.org/10.1007/s00380-009-1158-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-009-1158-x

Key words

Search

Navigation